Detalhe da pesquisa
1.
The initial molecular response predicts the deep molecular response but not treatment-free remission maintenance in a real-world chronic myeloid leukemia cohort.
Haematologica;
2024 May 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38695126
2.
Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial).
BMC Cancer;
24(1): 661, 2024 May 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38816821
3.
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Ann Hematol;
101(10): 2241-2255, 2022 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36040480
4.
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Br J Haematol;
187(3): 337-346, 2019 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31271217
5.
The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia.
Cancers (Basel);
14(19)2022 Sep 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36230624
6.
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells.
Sci Rep;
11(1): 6187, 2021 03 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33731863
7.
Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib.
Oncotarget;
11(26): 2560-2570, 2020 Jun 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32655840
8.
DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia.
Mol Oncol;
12(6): 814-829, 2018 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29575763